These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A long-acting C-natriuretic peptide for achondroplasia. Schneider EL; Carreras CW; Reid R; Ashley GW; Santi DV Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2201067119. PubMed ID: 35858423 [TBL] [Abstract][Full Text] [Related]
6. Magnetically-driven implantable pump for on-demand bolus infusion of short-acting glucagon-like peptide-1 receptor agonist. Lee SH; Min SH; Cho YC; Han JH; Kim MN; Kim CR; Ahn CH; Kim BH; Lee C; Cho YM; Choy YB J Control Release; 2020 Sep; 325():111-120. PubMed ID: 32619744 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes. Molina Vega M; Muñoz-Garach A; Tinahones FJ Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924 [TBL] [Abstract][Full Text] [Related]
8. Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents. van den Brink W; Emerenciana A; Bellanti F; Della Pasqua O; van der Laan JW Toxicol Appl Pharmacol; 2017 Apr; 320():51-59. PubMed ID: 28213092 [TBL] [Abstract][Full Text] [Related]
9. Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres. Li T; Chandrashekar A; Beig A; Walker J; Hong JKY; Benet A; Kang J; Ackermann R; Wang Y; Qin B; Schwendeman AS; Schwendeman SP Eur J Pharm Biopharm; 2021 Jan; 158():401-409. PubMed ID: 33122118 [TBL] [Abstract][Full Text] [Related]
10. Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release characteristics. Zhai J; Ou Z; Zhong L; Wang YE; Cao LP; Guan S Drug Deliv; 2020 Nov; 27(1):1667-1675. PubMed ID: 33241694 [TBL] [Abstract][Full Text] [Related]
11. Effects of the multilayer structures on Exenatide release and bioactivity in microsphere/thermosensitive hydrogel system. Wang P; Li Y; Jiang M Colloids Surf B Biointerfaces; 2018 Nov; 171():85-93. PubMed ID: 30015142 [TBL] [Abstract][Full Text] [Related]
12. Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway. Jia Y; Gong N; Li TF; Zhu B; Wang YX Pharmacol Res; 2015 Dec; 102():276-85. PubMed ID: 26546042 [TBL] [Abstract][Full Text] [Related]
13. Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans. Koska J; Sands M; Burciu C; D'Souza KM; Raravikar K; Liu J; Truran S; Franco DA; Schwartz EA; Schwenke DC; D'Alessio D; Migrino RQ; Reaven PD Diabetes; 2015 Jul; 64(7):2624-35. PubMed ID: 25720388 [TBL] [Abstract][Full Text] [Related]
14. Biological activity of AC3174, a peptide analog of exendin-4. Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977 [TBL] [Abstract][Full Text] [Related]
15. Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats. Rudinsky AJ; Adin CA; Borin-Crivellenti S; Rajala-Schultz P; Hall MJ; Gilor C Domest Anim Endocrinol; 2015 Apr; 51():78-85. PubMed ID: 25594949 [TBL] [Abstract][Full Text] [Related]
16. BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus. Ding L; Lu S; Wang Y; Chen H; Long W; Ma C; He E; Yan D; Tan F Pharmacol Res; 2017 Aug; 122():130-139. PubMed ID: 28619366 [TBL] [Abstract][Full Text] [Related]
17. Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist. Lear S; Seo H; Lee C; Lei L; Amso Z; Huang D; Zou H; Zhou Z; Nguyen-Tran VTB; Shen W Molecules; 2020 May; 25(11):. PubMed ID: 32481528 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats. Li X; Zhao Z; Li L; Zhou T; Lu W Drug Deliv; 2015 Jan; 22(1):86-93. PubMed ID: 24467493 [TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Tzefos M; Harris K; Brackett A Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes. LaRue S; Malloy J J Diabetes Sci Technol; 2015 Jul; 9(4):815-21. PubMed ID: 25759181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]